Escitalopram and amitriptyline lengthened QTc most, but antidepressants showed no early cardiac events in trials

Design

Individual participant data network meta-regression plus aggregate meta-analysis of double-blind RCTs

Population

8679 adults with depression (QTc); 52,398 in 139 trials (MACE)

Primary outcome

QTcF change at up to 8 weeks vs placebo

Effect

Escitalopram +8.7 ms (1.6 to 15.8); amitriptyline +5.3 ms (0.8 to 9.8); MACE risk difference 0.01% (-0.01 to 0.02)

This individual participant data network meta-regression used patient-level ECG data from 35 double-blind trials (8679 adults with depression) comparing ten antidepressants with placebo over eight weeks, adjusting for baseline QTc, age, sex, BMI, potassium and kidney function. Escitalopram lengthened QTc by 8.7 ms (95% credibility interval 1.6 to 15.8) and amitriptyline by 5.3 ms (0.8 to 9.8) against placebo. Once individual risk factors were taken into account, amitriptyline and escitalopram most often ranked highest for QTc prolongation; venlafaxine and vortioxetine most often ranked lowest. Effects varied a lot between people, especially for escitalopram, fluoxetine and mirtazapine.

A separate aggregate analysis of 139 trials (52,398 participants) found no association between antidepressants and early major cardiovascular events or non-suicidal death (risk difference 0.01%, -0.01% to 0.02%).

Taken together: QTc effects are real, drug-specific and dependent on the individual, but they did not translate into early cardiac events in trial populations. This supports choosing the antidepressant with the person's cardiac risk profile in mind — rather than avoiding antidepressants — and makes escitalopram a less automatic first choice in someone with QT risk factors.

• In people with QT risk factors, prefer an antidepressant with a smaller QTc effect over escitalopram or amitriptyline
• Venlafaxine and vortioxetine were most often among the lowest for QTc prolongation after adjustment
• Correct low potassium before starting a QT-prolonging antidepressant
• Repeat the ECG after dose increases when baseline QTc was borderline
• Reassure patients without risk factors that trials showed no early excess of cardiac events

Why it matters

It turns QTc from a blanket worry into a factor for choosing between drugs.

Don't overread it

Trials exclude high-risk people and run only eight weeks, so the absence of early events does not cover long-term use in cardiac patients.

The statistics, in plain English

A credibility interval is the Bayesian equivalent of a confidence interval; 1.6 to 15.8 ms means the escitalopram effect is real but its size is uncertain. The percentages are how often each drug ranked highest or lowest across simulations, not how many people were affected.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.